Modern Alpha Content Hub Diverging Paths: A Look at WisdomTree’s Best and Worst ETFs in Q1 2025 By WisdomTree InvestmentsApril 19, 2025
Expert Insights Opportunities in Biotechnology Will Follow Advancements in the Science By WisdomTree InvestmentsNovember 30, 2024
Modern Alpha Content Hub 2024 Superconvergence BioRevolution Series: A Blockbuster Gene Therapy? By WisdomTree InvestmentsAugust 31, 2024
Modern Alpha Content Hub Why We Loved Bill Gates’s Annual Letter By WisdomTree InvestmentsJanuary 6, 2024
Energy Infrastructure Content Hub VettaFi Voices On: The Outlook for 2024 By Heather BellDecember 8, 2023
Modern Alpha Content Hub Multiple Reasons to Bet on Biotech ETF WDNA By Todd ShriberSeptember 25, 2023
Modern Alpha Content Hub Biden’s “Cancer Moonshot” Brings Biotech Focus Back to U.S. By Karrie GordonSeptember 15, 2022
Modern Alpha Content Hub WisdomTree Once Again Wins “Asset Manager Website of the Year” By Karrie GordonJune 17, 2022
Modern Alpha Content Hub When Megatrends Intersect, Investors Can Benefit By Tom LydonFebruary 8, 2022
Modern Alpha Content Hub Rare Valuation Opportunities Afoot in Some Megatrends ETFs By Tom LydonJanuary 21, 2022
Modern Alpha Content Hub Harness Power, Promise of Genetics Research with WDNA By Tom LydonDecember 14, 2021
Modern Alpha Content Hub Historic Opportunity Afoot in Biotech Investing By Tom LydonNovember 3, 2021
Modern Alpha Content Hub The WDNA ETF: Investing in Healthcare Innovation By Tom LydonAugust 19, 2021
Modern Alpha Content Hub The BioRevolution: An ETF That Taps Into Nearly Everything By Max ChenJune 21, 2021
